12/29/2025
Blood disorders like thalassemia can be hard to treat. Patients' only option might be frequent blood transfusions throughout their life, and side effects like anemia can be tough to deal with alone.
But that's about to change.
Biologics by McKesson is proud to announce that we've been chosen by Agios Pharmaceuticals, Inc. to be the specialty pharmacy provider for AQVESME® (mitapivat). This drug treats anemia in adults with alpha- or beta-thalassemia, building on the 2022 approval of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency (PKD).
Pyrukynd® (mitapivat) is still available to treat PKD, while AQVESME® provides a new 100-mg strength option for treating thalassemia.
Because AQVESME® (mitapivat) is part of a Risk Evaluation and Mitigation Strategy (REMS) program, we have a dedicated REMS Care Team that works directly with patients to provide support, answer questions, and help manage side effects.
We're proud to be able to offer a safe, effective treatment option that can help patients face the challenges of this disease and live healthier lives.
Find out more: https://biologics.mckesson.com/aqvesme-mitapivat-fda-approved-for-adults-with-thalassemia-exclusively-available-at-biologics-by-mckesson